Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin tregopil - Biocon

Drug Profile

Insulin tregopil - Biocon

Alternative Names: GW 843362; Hexyl Insulin M2; Hexyl insulin monoconjugate 2; HIM2; IN-105; NIN-058; Oral prandial insulin - Biocon

Latest Information Update: 16 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nobex Corporation
  • Developer Biocon; Bristol-Myers Squibb
  • Class Antihyperglycaemics; Hormones; Insulins; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 16 Jun 2023 Phase-Ib development is ongoing Germany (PO, Tablet) (Biocon pipeline, June 2023)
  • 27 Jun 2022 Biocon terminates a phase I trial in Type 1 diabetes mellitus in Germany (PO), before starting part 2 of study (NCT04141423)
  • 28 Oct 2019 Phase-I clinical trials in Type 1 diabetes mellitus in Germany (PO) (NCT04141423)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top